What Are Nontuberculous Mycobacteria?
Nontuberculous mycobacteria (NTM) are a large and diverse group of mycobacterial species found ubiquitously in the environment, including water systems, soil, and aerosols. Unlike Mycobacterium tuberculosis, NTM are not transmitted person-to-person and are instead acquired through environmental exposure.
More than 200 distinct NTM species and subspecies have been described to date. Of these, an estimated 25–60 species are recognized as clinically relevant causes of infection in humans, depending on host factors, exposure risk, and evolving clinical evidence. Many additional species are increasingly identified in clinical samples, and their pathogenic potential continues to be clarified as diagnostic resolution improves.
NTM are now recognized as an important and growing cause of pulmonary and extrapulmonary disease worldwide.
Who Is Affected by NTM Disease?
NTM disease disproportionately affects certain patient populations, though infection can occur in individuals without known risk factors.
High-risk populations include:
- Patients with bronchiectasis
- Chronic obstructive pulmonary disease (COPD)
- Cystic fibrosis (CF)
- Prior pulmonary tuberculosis
- Individuals receiving immunosuppressive or biologic therapies
- Patients with primary or acquired immune deficiencies
- Older adults, particularly postmenopausal women without obvious underlying lung disease
The increasing prevalence of NTM disease is thought to reflect a combination of aging populations, improved survival in chronic lung disease, increased use of immunomodulatory therapies, and greater exposure to engineered water systems that favor NTM growth.
How NTM Cause Disease: Routes of Infection
While pulmonary infection is the most common manifestation, NTM disease is not limited to the respiratory tract.
Respiratory Exposure
Inhalation of aerosolized NTM from water sources (showers, humidifiers, plumbing systems) leads primarily to pulmonary disease in susceptible hosts.
Skin and Soft-Tissue Exposure
Direct inoculation through trauma, surgery, cosmetic procedures, injections, or indwelling devices results in skin, soft-tissue, and post-procedural infections — particularly associated with rapidly growing mycobacteria.
Disseminated Infection
Occurs when NTM spread beyond the site of entry, most common in severely immunocompromised individuals. Can involve bloodstream, lymph nodes, bone, or other organs.
Clinical Manifestations of NTM Infection
Pulmonary Disease
NTM pulmonary disease (NTM-PD) is the most common presentation — a chronic, slowly progressive infection characterized by chronic cough, fatigue, weight loss, dyspnea, recurrent respiratory infections, and radiographic findings such as nodules, cavities, or bronchiectasis. Symptoms often overlap with other chronic lung conditions, contributing to delayed recognition and diagnosis.
Extrapulmonary Disease
NTM can also cause skin and soft-tissue infections (often following trauma or procedures), lymphadenitis (particularly in children), bone and joint infections, and disseminated disease in patients with advanced immunosuppression.
Diversity of NTM: Species and Complexes
NTM are best understood as a broad and heterogeneous group of organisms, rather than a single disease entity. Clinically relevant NTM vary widely in pathogenicity, tissue tropism, resistance profiles, and response to therapy. Many are grouped into species complexes, reflecting genetic relatedness and overlapping clinical behavior.
Mycobacterium avium Complex (MAC)
Includes M. avium, M. intracellulare, and related species. Most common cause of NTM pulmonary disease globally. Common in patients with bronchiectasis, COPD, and older adults. Increasing macrolide resistance reported in some regions, often associated with prior therapy.
Mycobacterium abscessus Complex
Rapidly growing mycobacteria highly prevalent in cystic fibrosis and bronchiectasis populations. Associated with severe, progressive lung disease. Notable for intrinsic and inducible antimicrobial resistance. Subspecies-level differences significantly impact treatment response.
Mycobacterium fortuitum Group
Rapidly growing species associated with pulmonary disease, catheter-related infections, post-surgical infections, and trauma-related skin disease. Often more susceptible to antibiotics than M. abscessus, though resistance patterns are evolving.
Mycobacterium chelonae
Rapidly growing species that frequently causes skin, soft-tissue, ocular, and disseminated infections. Particularly important in immunocompromised hosts. Demonstrates variable resistance profiles across isolates.
Mycobacterium kansasii
Causes TB-like pulmonary disease. Historically linked to specific geographic regions. Generally more responsive to treatment, though resistance trends are emerging.
Mycobacterium xenopi
More prevalent in Europe and parts of Canada. Typically affects patients with underlying lung disease. Associated with significant morbidity in advanced cases.
Other Clinically Relevant NTM
Additional species include M. marinum (aquatic exposure and skin infections), M. ulcerans (necrotizing skin disease in specific regions), M. simiae, M. gordonae, M. szulgai, and M. haemophilum. Many are encountered infrequently but may be clinically significant in specific hosts or exposure settings.
Geographic Variability of NTM
The distribution of nontuberculous mycobacteria varies widely by geographic region, reflecting differences in climate, water infrastructure, soil composition, and environmental exposure patterns. NTM are not uniformly distributed pathogens; specific species and complexes tend to cluster regionally, shaping both disease epidemiology and clinical expectations.
Environmental Drivers of Geographic Variation
Several environmental factors influence which NTM species predominate in a given region:
- Climate and humidity: Warm, humid, and subtropical environments favor the growth and persistence of many NTM species
- Water systems: Municipal water treatment practices, plumbing materials, and biofilm formation strongly influence NTM exposure
- Soil composition and land use: Certain species are more prevalent in regions with specific soil types or agricultural practices
- Aerosolization risk: Showering, humidifiers, hot tubs, and industrial water systems contribute to inhalational exposure
Because NTM are environmentally acquired, regional ecology directly shapes clinical epidemiology.
Regional Patterns in NTM Species Distribution
North America
Mycobacterium avium complex is the most commonly isolated cause of NTM pulmonary disease. M. abscessus complex is particularly prevalent in cystic fibrosis populations. M. kansasii shows regional clustering, historically associated with certain urban and industrial areas.
Europe
Higher relative prevalence of Mycobacterium xenopi and Mycobacterium malmoense. M. avium complex remains common but with different species proportions compared to North America.
Asia
Greater diversity of clinically relevant NTM species. Higher prevalence of M. abscessus, M. fortuitum, and M. simiae. Regional variation even within individual countries.
Australia and Oceania
High rates of NTM pulmonary disease in certain regions. Environmental conditions favor both slow-growing and rapidly growing NTM. Distinct species patterns compared to Europe and North America.
Tropical and Subtropical Regions
Increased prevalence of skin and soft-tissue NTM infections. Species such as M. marinum and M. ulcerans are geographically restricted but clinically significant.
Clinical Implications of Geographic Heterogeneity
Geographic variability has direct consequences for patient care:
- Diagnostic expectations: Clinicians practicing in different regions encounter different "common" NTM species
- Treatment planning: Resistance patterns and expected treatment responses vary by species and region
- Epidemiologic interpretation: A species that is rare in one region may be a frequent pathogen in another
- Risk assessment: Environmental exposure histories are more informative in some regions than others
Local epidemiology plays an important role in how clinicians interpret positive cultures and plan further evaluation.
Antimicrobial Resistance and Its Evolution
Antimicrobial resistance presents one of the greatest challenges in NTM management.
Key factors include:
- Intrinsic resistance common to many NTM species
- Acquired resistance during prolonged or incomplete therapy
- Strain-level variability within the same species
- Inducible resistance mechanisms that emerge only after antibiotic exposure
Resistance patterns are not static and continue to evolve, complicating treatment decisions and contributing to variable outcomes.
The Diagnostic Challenge
Despite growing recognition of NTM disease, diagnosis remains difficult for several reasons:
Slow Growth
Many NTM species require 2–8 weeks to grow in culture, delaying species identification and treatment decisions.
Misidentification
Traditional methods may fail to distinguish between closely related species with different treatment implications.
Mixed Infections
Patients may harbor multiple NTM species simultaneously, which culture-based methods often miss.
Resistance Uncertainty
Phenotypic susceptibility testing requires additional weeks after culture, leaving clinicians without resistance data during critical early treatment windows.
These challenges contribute to diagnostic delays, empiric therapy that may not match the organism, and suboptimal outcomes.
A Better Approach to NTM Identification
Next-generation sequencing offers a solution. By sequencing directly from clinical samples, molecular methods can identify NTM species in days rather than weeks — without requiring organism growth.
This enables earlier species identification, detection of mixed infections, and genotypic resistance insight before phenotypic testing is possible.
Learn About NTM-SeqContinued advances in clinical recognition and species-level understanding will be essential to improving patient outcomes and addressing the growing global burden of NTM disease.